CorVista Health, Inc., a Toronto, CA-based digital health company dedicated to improving cardiovascular disease diagnosis, closed a $65m Series C equity financing.
This round, which brought the total amount raised to nearly $100, was led by Ambix Life Science Fund I, L.P., joined by MedVenture Partners, Inc. as well as several new and previous investors.
Additionally, ongoing clinical research is being accelerated for the CorVista System to assess for coronary artery disease as well as elevated left ventricular end diastolic pressure and elevated mean pulmonary artery pressure, hallmarks of heart failure and pulmonary hypertension, respectively.
The company intends to use the funds accelerate product development for the CorVista System and scale its infrastructure ahead of commercialization
Led by Don Crawford, Chief Executive Officer, CorVista System provides a non-invasive, point-of-care solution that allows physicians to rapidly test for heart disease. CorVista System is a non-invasive point-of-care solution that is intended to synchronously collect and apply machine learning to a patient’s cardiac and hemodynamic signals to predict the likelihood of cardiovascular diseases without the use of radiation, contrast agents, injections, fasting or exercise. Within minutes of the test, the CorVista® Analysis is available in a secure web portal to aid physicians in rapidly diagnosing and treating patients with suspected cardiovascular disease, answering important clinical questions to guide better treatment decisions.
The CorVista System is an investigational device limited by federal law to investigational use. CorVista System is not available for commercial distribution.
The company is a subsidiary of Toronto-based Analytics For Life Inc.